Hill+Knowlton Strategies has brought on Penny Mitchell to lead the firm’s U.S. health practice as an EVP.
She will join the firm at the end of February, based in New York and reporting to U.S. president and CEO Beth Balsam.
“In addition to building upon the U.S. team’s existing strengths in the pharmaceutical and provider space, I see great cross-practice collaboration opportunities at the firm to create best-in-class integrated solution to address the multifaceted and evolving needs of healthcare clients,” Mitchell said.
Mitchell previously worked at dna Communications, a healthcare specialty division of Weber Shandwick, as SVP and director of new business. Prior, she was SVP, senior partner, and director of business development and client services at FleishmanHillard health and wellness boutique Togorun. Mitchell has also worked at FleishmanHillard, where she was co-chair of the global healthcare practice, and Porter Novelli.
Mitchell will succeed EVP Tali Mackay, who was promoted last year to lead the firm’s western region.
Dna has not yet replaced Mitchell in the role, said Michael Rinaldo, EVP and GM of the firm.
“We wish [Mitchell] well in her next endeavors and are grateful for her contribution to dna,” he said, via email. “We have not yet named her replacement, and are continuing to ensure we have the right people and talent in place, as always, to best service our clients.”
This story originally appeared in PRWeek.
